The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib
- 1 January 2013
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 11 (11), 1766-1800
- https://doi.org/10.1039/c2ob27003j
Abstract
Imatinib (1), nilotinib (2) and dasatinib (3) are Bcr-Abl tyrosine kinase inhibitors approved for the treatment of chronic myelogenous leukemia (CML). This review collates information from the journal and patent literature to provide a comprehensive reference source of the different synthetic methods used to prepare the aforementioned active pharmaceutical ingredients (API's).Keywords
This publication has 70 references indexed in Scilit:
- An expeditious synthesis of imatinib and analogues utilising flow chemistry methodsOrganic & Biomolecular Chemistry, 2013
- Completely N1-Selective Palladium-Catalyzed Arylation of Unsymmetric Imidazoles: Application to the Synthesis of NilotinibJournal of the American Chemical Society, 2011
- Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most casesChemical Science, 2010
- A Highly Active Catalyst for Pd-Catalyzed Amination Reactions: Cross-Coupling Reactions Using Aryl Mesylates and the Highly Selective Monoarylation of Primary Amines Using Aryl ChloridesJournal of the American Chemical Society, 2008
- Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec)Nuclear Medicine and Biology, 2007
- Improved Synthesis of Substituted 6,7-Dihydroxy-4-quinazolineamines: Tandutinib, Erlotinib and GefitinibMolecules, 2006
- Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProceedings of the National Academy of Sciences, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)Archiv der Pharmazie, 1996
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988